Prebiotic oligosaccharides in early life alter gut microbiome development in male mice while supporting influenza vaccination responses.


Journal

Beneficial microbes
ISSN: 1876-2891
Titre abrégé: Benef Microbes
Pays: Netherlands
ID NLM: 101507616

Informations de publication

Date de publication:
19 Apr 2019
Historique:
pubmed: 19 2 2019
medline: 8 8 2019
entrez: 19 2 2019
Statut: ppublish

Résumé

Beneficial modulation of the gut microbiota is an attractive therapeutic approach to improve the efficacy of vaccine-induced immunity. In this study, mice were supplemented with the prebiotic milk oligosaccharide 2'-fucosyllactose (2'FL) as well as a complex mixture of immune modulatory prebiotic short-chain galacto-oligosaccharides and long-chain fructo-oligosaccharides (scGOS/lcFOS) from different stages in early life. Adult mice were vaccinated with trivalent influenza vaccine (TIV) and both development of the gut microbiota and antibody-mediated vaccine responses were followed over time. Within the control group, female mice demonstrated a larger antibody response to TIV vaccination than male mice, which was accompanied by enhanced cytokine production by splenocytes and a higher percentage of plasma cells in skin draining lymph nodes. In addition, the prebiotic diet improved vaccine-specific antibody responses in male mice. Introduction of prebiotics into the diet modulated the gut microbiota composition and at the genus level several bacterial groups showed a significant interaction effect which potentially contributed to the immunological effects observed. This study provides insight in the effect of scGOS/lcFOS/2'FL in influenza vaccination antibody production.

Identifiants

pubmed: 30773928
doi: 10.3920/BM2018.0098
doi:

Substances chimiques

Antibodies 0
Cytokines 0
Influenza Vaccines 0
Oligosaccharides 0
Prebiotics 0

Types de publication

Journal Article

Langues

eng

Pagination

279-291

Auteurs

L W J van den Elsen (LWJ)

1 Malaghan Institute of Medical Research, Gate 7 Victoria University, Kelburn Parade, Wellington 6012, New Zealand.

S Tims (S)

1 Malaghan Institute of Medical Research, Gate 7 Victoria University, Kelburn Parade, Wellington 6012, New Zealand.

A M Jones (AM)

1 Malaghan Institute of Medical Research, Gate 7 Victoria University, Kelburn Parade, Wellington 6012, New Zealand.

A Stewart (A)

1 Malaghan Institute of Medical Research, Gate 7 Victoria University, Kelburn Parade, Wellington 6012, New Zealand.

B Stahl (B)

2 Danone Nutricia Research, Departments of Immunology/Microbiology/Human Milk Research, Uppsalalaan 12, 3584 CT Utrecht, the Netherlands.

J Garssen (J)

2 Danone Nutricia Research, Departments of Immunology/Microbiology/Human Milk Research, Uppsalalaan 12, 3584 CT Utrecht, the Netherlands.
3 Utrecht University, Faculty of Science, Department of Pharmaceutical Sciences, Division of Pharmacology, Universiteitsweg 99, 3584 CG Utrecht, the Netherlands.

J Knol (J)

2 Danone Nutricia Research, Departments of Immunology/Microbiology/Human Milk Research, Uppsalalaan 12, 3584 CT Utrecht, the Netherlands.
4 Wageningen University & Research, 6708 PB Wageningen, the Netherlands.

E E Forbes-Blom (EE)

1 Malaghan Institute of Medical Research, Gate 7 Victoria University, Kelburn Parade, Wellington 6012, New Zealand.

B Van't Land (B)

2 Danone Nutricia Research, Departments of Immunology/Microbiology/Human Milk Research, Uppsalalaan 12, 3584 CT Utrecht, the Netherlands.
5 University Medical Center Utrecht, The Wilhelmina Children's Hospital, Laboratory of Translational Immunology, Heidelberglaan 100, 3584 CX Utrecht, the Netherlands.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH